3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
378
Pituitary Neoplasms
158
Multiple Endocrine Neoplasia Type 1
150
Thyroid Cancer, Papillary
122
Pheochromocytoma
107
Carcinoma, Neuroendocrine
93
Thyroid Neoplasms
74
Paraganglioma
68
Carcinoid Tumor
66
Neoplasms
54
Thyroid Carcinoma, Anaplastic
50
Adrenocortical Carcinoma
47
Adrenal Gland Neoplasms
46
Neoplasm Metastasis
40
Insulinoma
39
Pancreatic Neoplasms
36
Gastro-enteropancreatic neuroendocrine tumor
36
Adenoma, Islet Cell
36
Carcinoma, Medullary
29
Neuroblastoma
28
Adenocarcinoma, Follicular
28
Hyperaldosteronism
25
Prostatic Neoplasms
24
Lung Neoplasms
24
Obesity
23
Brain Neoplasms
22
Pituitary Diseases
21
Differentiated Thyroid Cancer
20
Cushing Syndrome
20
Sarcoma
19
Interventions
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
High-grade Extra Pulmonary Neuroendocrine Cancer
×
Endocrine
×
Clear all
NCT04042714
2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2
Terminated
14 enrolled